The early work on aberrant MUC1 expression in breast cancer was extended by studies in other types of adenocarcinomas and squamous cell carcinomas, as well as hematologic malignancies, that continue to shed light on the involvement of MUC1 in cancer initiation and progression. This evidence concerns the gene MUC1 and breast carcinoma.